Features
Neuroprotection: Retina's Next Frontier?
At OIS Retina in Montreal, Riad Sherif, MD, discussed Oculis’s optic neuritis program and why neuroprotection may represent the next frontier in retinal therapeutics.
By Riad Sherif, MD
Alkeus Launches Phase 3 Stargardt Trial
At OIS Retina, Carlos Quezada Ruiz, MD, highlighted the launch of the global phase 3 NORTHSTAR trial evaluating oral gildeuretinol for Stargardt disease.
By Carlos Quezada Ruiz, MD
Stuart Therapeutics Spotlights Topical RP Program
At OIS Retina, Eric Schlumpf discussed the company’s collagen mimetic peptide platform for retinitis pigmentosa, now in preclinical development.
By Eric Schlumpf
The Economics of Home OCT
At ASRS 2026, Sean Berkowitz, MD, MBA, examined the payer costs and physician workload associated with home OCT monitoring for wet AMD.
By Jim Gallagher, senior managing editor
Merck Highlights Early Tiespectus Data
At the ASRS meeting in Montreal, Baruch D. Kuppermann, MD, PhD, presented BRVO findings from the phase 1/2a RIOJA program evaluating the investigational VEGF/Tie2 bispecific.
By Jim Gallagher, senior managing editor
Lessons From the ARCHER Trial
Margaret A. Chang, MD, MS, discusses how findings from the phase 2 ARCHER trial informed the design of the ongoing phase 3 ARCHER II study of vonaprument, which is expected to read out later this year.
By Margaret Chang, MD
Does Timing Matter in Gene Therapy for nAMD?
Carl C. Awh, MD, FASRS, discusses 2-year phase 2b PRISM results showing durable outcomes with investigational 4D-150 in patients with recently diagnosed neovascular age-related macular degeneration.
By Carl C. Awh, MD
A First Look at Phase 2 ArMaDa Data
Arshad M. Khanani, MD, FASRS, discusses phase 2 findings for OCU410, an investigational gene therapy for geographic atrophy. A phase 3 program is expected to begin later this year.
By Arshad M. Khanani, MD, MA, FASRS
The New Rules of Retina Drug Development
In a panel discussion at the Retina Innovation Summit in Montreal, regulatory experts, drug developers, academic advisors, and investors discussed how evolving FDA guidance is reshaping the path from clinical trials to approval.
By Jim Gallagher, senior managing editor
ORG Detects Retinal Dysfunction Before Structural Changes
At ASRS 2026, Kareem Moussa, MD, presented early data suggesting optoretinography may identify photoreceptor dysfunction in diabetic eyes before conventional imaging reveals abnormalities.
By Jim Gallagher, senior managing editor
The Promise of Gene Therapy
With phase 3 topline data for sura-vec expected later this year, Arshad M. Khanani, MD, FASRS, reflects on how gene therapy could transform long-term treatment for nAMD.
By Arshad M. Khanani, MD, MA, FASRS
Can Stem Cell Therapy Slow GA?
Phase 1b data for ASP7317, presented at ASRS, showed a favorable safety profile, encouraging visual acuity findings, and stabilization of geographic atrophy in patients with advanced disease.
By VIVIENNE HAU, MD, PHD
OLN324: Why Size May Matter
David A. Eichenbaum, MD, FASRS, and Veeral S. Sheth, MD, MBA, discuss phase 1 JADE findings and how OLN324's small-format design may contribute to improved retinal drying in nAMD and diabetic macular edema.
By David A. Eichenbaum, MD, Veeral S. Sheth, MD, MBA, FACS
Expanding Optogenetics to Geographic Atrophy
Jordi Monés, MD, PhD, discusses the rationale for evaluating MCO-010 in GA following encouraging findings in retinitis pigmentosa and Stargardt disease.
By Jordi Monés, MD, PhD
Drs. Berrocal Reflect on ASRS 2026
ASRS 2026 meeting program chair Audina M. “Nina” Berrocal, MD, FASRS, joins Maria H. Berrocal, MD, to discuss the meeting’s highlights, surgical sessions, and educational approach.
By Audina M. Berrocal, MD, Maria H. Berrocal, MD
What Retina Specialists Have Learned From TRUCKEE
Carl J. Danzig, MD, reviews 4.5 years of real-world findings showing sustained anatomic improvements, longer treatment intervals, and a favorable safety profile with faricimab in neovascular AMD.
By Carl Danzig, MD
Treating CME Without Reactivating Retinitis
Data from a retrospective Emory Eye Center series suggest most eyes with CME following infectious retinitis achieved resolution without disease reactivation, although prolonged treatment and close monitoring were often required.
By Sruthi Arepalli, MD
Could Gene Therapy Change Retina Care for Rural Veterans?
Drawing on his experience caring for veterans in northern California, Frank Brodie, MD, MBA, explains why gene therapy may be particularly meaningful for patients who travel long distances for routine anti-VEGF treatment.
By Frank Brodie, MD, MBA
What Imaging Reveals About OCU410
At ASRS 2026, Jay Chhablani, MD, reviews quantitative imaging analyses showing reduced structural progression with gene therapy OCU410, along with a favorable safety profile.
By Jay Chhablani, MD
5 Years of Gene Therapy: What the OPTIC Data Show
Szilárd Kiss, MD, FASRS, reviews 5-year findings from the OPTIC program in neovascular AMD patients with high anti-VEGF treatment needs, showing stable vision, substantially reduced treatment burden, and a favorable long-term safety profile.
By Szilárd Kiss, MD
Recognizing the Best of JVRD in 2026
Journal of VitreoRetinal Diseases Editor-in-Chief Timothy G. Murray, MD, MBA, FASRS, reviews this year's most influential articles and discusses the journal’s next chapter as it transitions to a self-publishing model.
By Timothy G. Murray, MD, MBA, FACS
Real-World Study Finds Similar Rates of GA Lesion Growth During Treatment With Izervay or Syfovre
Josh O. Wallsh, MD, presented a same-eye comparison of avacincaptad pegol and pegcetacoplan at ASRS 2026, finding no statistically significant difference in geographic atrophy lesion growth rates.
By Josh O. Wallsh, MD
Evaluating Complement Inhibition Across GA Populations
An AI-assisted real-world analysis found reduced RPE and photoreceptor loss after pegcetacoplan treatment in patients with GA, including those with concomitant neovascular AMD.
By Hasenin Al-Khersan, MD
K8 Delivers Encouraging Phase 2 Results
A sustained-release inflammasome inhibitor reduced lesion growth while demonstrating a statistically significant BCVA benefit in patients with geographic atrophy.
By Jayakrishna Ambati, MD
News
CMS Proposal Would Cut Payment for Same-Day Injection Visits
The proposed Physician Fee Schedule for 2027 includes changes affecting intravitreal injections, E/M services, and physician payment.
By Jim Gallagher, senior managing editor
Articles
ASRS President Reflects on a Year of Change
As his term comes to a close, Geoffrey G. Emerson, MD, PhD, FASRS, discusses scientific advances, physician advocacy, and the collaborative leadership behind ASRS.
By Geoffrey G. Emerson, MD, PhD, FASRS
OTX-TKI: Inside the SOL-1 Data
At ASRS 2026, Dilsher S. Dhoot, MD, FASRS, shared additional phase 3 SOL-1 data on vision maintenance, rescue treatment, and safety with investigational OTX-TKI (Axpaxli) in neovascular AMD.
By Dilsher S. Dhoot, MD